The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL–Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group
Open accessAbstract
Purpose: A novel therapeutic approach is urgently needed for BCR-ABL–positive acute lymphoblastic leukemia (ALL). In this study, we assessed the efficacy and feasibility of chemotherapy combined with imatinib. Patients and Methods: A phase II study of imatinib-combined chemotherapy was conducted for newly diagnosed BCR-ABL–positive ALL in adults. Eighty patients were entered into the trial between September 2002 and January 2005. Results: Remission induction therapy resulted in complete remission (CR) in 77 patients (96.2%), resistant disease in one patient, and early death in two patients, as well as polymerase chain reaction negativity of bone marrow in 71.3%. The profile and incidence of severe toxicity were not different from those associated with our historic chemotherapy-alone regimen. Relapse occurred in 20 patients after median CR duration of 5.2 months. Allogeneic hematopoietic stem-cell transplantation (HSCT) was performed for 49 patients, 39 of whom underwent transplantation during their first CR. The 1-year event-free and overall survival (OS) rates were estimated to be 60.0%, and 76.1%, respectively, which were significantly better than those for our historic controls treated with chemotherapy alone (P < .0001 for both). Among the current trial patients, the probability for OS at 1 year was 73.3% for those who underwent allogeneic HSCT, and 84.8% for those who did not. Conclusion: Our results demonstrated that imatinib-combined regimen is effective and feasible for newly diagnosed BCR-ABL–positive ALL. Despite a relatively short period of observation, a major potential of this treatment is recognized. Longer follow-up is required to determine its overall effect on survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Larson, R., Dodge, R., Burns, C., Lee, E., Stone, R., Schulman, P., Duggan, D., Davey, F., Sobol, R., & Frankel, Sr. (1995) · Blood · doi:10.1182/blood.v85.8.2025.bloodjournal8582025 · Cited by 626
Thomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
Ottmann, O. G. (2002) · Blood · doi:10.1182/blood-2001-12-0181 · Cited by 555
Ha, S., Karhi, K. K., Rayter, S., Heisterkamp, N., Eridani, S., Powle, R., Lawler, S. D., Groffen, J., Foulkes, J. G., Greaves, M. F., et al. (1987) · Nature · doi:10.1038/325635a0 · Cited by 434
Hermans, A., Heisterkamp, N., von Lindern, M., van Baal, S., Meijer, D., van der Plas, D., Wiedemann, L. M., Groffen, J., Bootsma, D., & Grosveld, G. (1987) · Cell · doi:10.1016/0092-8674(87)90007-9 · Cited by 387
Annino, L., Vegna, M. L., Camera, A., Specchia, G., Visani, G., Fioritoni, G., Ferrara, F., Peta, A., Ciolli, S., Deplano, W., et al. (2002) · Blood · doi:10.1182/blood.v99.3.863 · Cited by 352
Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia
Faderl, S., Kantarjian, H. M., Talpaz, M., & Estrov, Z. (1998) · Blood · doi:10.1182/blood.v91.11.3995 · Cited by 335
Wetzler, M., Dodge, R. K., Mrózek, K., Carroll, A. J., Tantravahi, R. V., Block, A. W., Pettenati, M. J., Beau, M. M. L., Frankel, S. R., Stewart, C. C., et al. (1999) · PubMed · doi:10.1182/blood.v93.11.3983 · Cited by 312
Secker‐Walker, L. M., Prentice, H. G., Durrant, J., Rchards, S., Hall, E., & Harrison, G. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.d01-2053.x · Cited by 241
Expression of a Distinctive BCR-ABL Oncogene in Ph 1 -Positive Acute Lymphocytic Leukemia (ALL)
Clark, S. S., McLaughlin, J., Timmons, M., Pendergast, A. M., Ben-Neriah, Y., Dow, L. W., Crist, W., Rovera, G., Smith, S. D., & Witte, O. N. (1988) · Science · doi:10.1126/science.3422516 · Cited by 235
Lee, S., Kim, Y.-J., Min, C.-K., Kim, H.-J., Eom, K.-S., Kim, D.-W., Lee, J.-W., Min, W.-S., & Kim, C.-C. (2005) · Blood · doi:10.1182/blood-2004-09-3785 · Cited by 196
Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia
Faderl, S. H., Kantarjian, H. M., Thomas, D. A., Cortes, J. E., Giles, F. J., Pierce, S., Albitar, M. X., & Estrov, Z. E. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009148847 · Cited by 150
Espérou, H., Boiron, J., Cayuela, J., Blanchet, O., Kuentz, M., Jouet, J. P., Milpied, N. J., Cahn, J.-Y. Y., Faucher, C., Bourhis, J.-H., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703951 · Cited by 68
Cited by
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Foà, R., Bassan, R., Vitale, A., Elia, L., Piciocchi, A., Puzzolo, M.-C., Canichella, M., Viero, P., Ferrara, F., Lunghi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016272 · Cited by 522
Modern Therapy of Acute Lymphoblastic Leukemia
Bassan, R., & Hoelzer, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1382 · Cited by 485
Foà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351403 · Cited by 462
Vignetti, M., Fazi, P., Cimino, G., Martinelli, G., Di Raimondo, F., Ferrara, F., Meloni, G., Ambrosetti, A., Quarta, G., Pagano, L., et al. (2007) · Blood · doi:10.1182/blood-2006-10-052746 · Cited by 374
Metadata
- Authors
- Yanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N., Yagasaki, F., Kobayashi, T., Ueda, Y., Takeuchi, M., Miyawaki, S., Maruta, A., Emi, N., Miyazaki, Y., Ohtake, S., Jinnai, I., Matsuo, K., Naoe, T., & Ohno, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-01-20
- Volume
- 24
- Issue
- 3
- Pages
- 460-466
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148854558
- Cited by
- 454
- References
- 18
- FWCI
- 24.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.